SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.
SideROS bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells, refractory to conventional treatments and associated to metastasis and relapse. The role of iron is ubiquitous whatever the origin of cancer cells, suggesting that our small molecules can target various types of cancer.
Dr Raphaël Rodriguez, Research Director at Curie Institute, performed his PhD studies under the supervision of Prof Sir Jack E. Baldwin and Prof Maurice Santelli at the University of Oxford and in Marseille, where he completed the synthesis of structur ally complex natural products by means of pericyclic processes. He joined The University of Cambridge in November 2005 as a postdoctoral fellow, together with Prof. Steve Jackson (Gurdon Institute, UK), they firmly established a link between G-quadruplex DNA structures and genomic instability. Raphaël joined the CNRS as a group leader in 2012 and was promoted Director of Research at Institut Curie in 2017.....More
Dr Raphaël Rodriguez, Founder
Our first lead product, the ironomycin, is a chemical small molecule, highly active in vitro and in vivo.
Paris, Aug. 27. 2020 – Based on promising proof of concept results, SideROS will join Paris Biotech Santé incubator to initiate non-clinical pivotal investigations prior to first-in-man studies
SideROS, a French biotechnology company specialized in oncology, announced a closing of €1 M funding to tackle cancer relapse and metastasis. SideROS bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells.
The €1 M funding from private and public investment is brought half by a pool of Business Angels with international expertise in the pharmaceutical industry in the form of equity, and half by the support of Bpifrance and Région Ile-de-France in the form of grants and loans.
“This investment from qualified Business Angels and public support will allow us to accelerate our development and reach strategic milestones to move forward to pivotal regulatory toxicology studies in early 2021 and to the design of our first clinical trial planned for 2022 aiming at improving the condition of patients affected by life-threatening diseases lacking an effective treatment. We are very proud to have been selected by Paris Biotech Santé, a new step in SideROS structural development” stated Lucie Mondoulet, CEO at SideROS.
Basée sur les travaux de Raphaël Rodriguez, directeur de recherche au CNRS, la start-up SideROS développe de nouvelles stratégies anticancéreuses qui ciblent le fer contenu dans les cellules souches résistantes aux traitements.
Microscopie à fluorescence d’un modèle de cellules souches cancéreuses. Autour du noyau, en bleu, on voit une co-localisation entre l’ironomycine, en vert et les lysosomes (organites cellulaires qui permettent la digestion intracellulaire grâce à des enzymes), en rouge.
Forts de cette piste extrêmement prometteuse et inédite, Raphaël Rodriguez et Robin Rivaton, économiste et essayiste, ont fondé une start-up pour valoriser l’ironomycine.
« Il a d’abord fallu publier beaucoup de travail académique, puis discuter avec des contacts dans les biotechnologies et les milieux économiques, se souvient le chimiste. Lancer une start-up demande le bon timing. Ni trop tôt ni trop tard. ».
Une approche d’influence anglo-saxonne, inspirée par son année de thèse à Oxford et ses sept années de postdoc à Cambridge.
SideROS was selected for the 2020 EIT Health Headstart program providing emerging companies with mentorship and funding opportunities for their innovative products and services aiming to improve the lives of European patients and citizens.
Ninety-six start-ups from across Europe have been selected to take part in the annual EIT Health Headstart programme. The start-ups picked up are granted mentoring and business support, and financial support of up to €50,000, and will make valuable contacts within the health innovation ecosystem via EIT Health’s vast network.
Sideors bridges innovation via research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells. Their innovative approach uses small molecules that show the potential to target various types of cancer, thereby revolutionising treatment.